Macrophage activation syndrome associated with adult-onset Still's disease: a multicenter retrospective analysis

被引:40
|
作者
Wang, Ran [1 ]
Li, Ting [2 ]
Ye, Shuang [2 ]
Tan, Wenfeng [3 ]
Zhao, Cheng [4 ]
Li, Yisha [5 ]
de Bao, Chun [1 ]
Fu, Qiong [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Rheumatol, Shanghai 200001, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Rheumatol, South Campus, Shanghai 200001, Peoples R China
[3] Nanjing Med Univ, Affiliate Hosp 1, Dept Rheumatol, Nanjing 210000, Peoples R China
[4] Nanjing Univ, Med Sch, Affiliated Nanjing Drum Tower Hosp, Dept Rheumatol, Nanjing 210000, Peoples R China
[5] Cent South Univ, Xiangya Hosp, Dept Rheumatol, Changsha 410000, Peoples R China
关键词
Adult-onset Still's disease; Macrophage activation syndrome; Treatment; HEMOPHAGOCYTIC SYNDROME; OUTCOMES; PATIENT;
D O I
10.1007/s10067-020-04949-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To explore the clinical features, treatments, and prognostic factors of adult-onset Still's disease (AOSD)-associated macrophage activation syndrome (MAS), we conducted a multicenter retrospective clinical study of AOSD-associated MAS patients. Methods AOSD patients were collected from six tertiary hospitals in China. Medical charts were reviewed and clinical information was recorded and analyzed. Results There were 447 AOSD patients enrolled into this retrospective clinical study. Among them, 55 were diagnosed with MAS. Liver dysfunction was the most reliable predictive factor for the screening of MAS in AOSD patients (OR = 75.744, 95%CI = 23.015-249.284, p < 0.0001). In multivariate analysis, clinical features including platelets < 100 x 10(9)/L (OR = 9.546, p = 0.005), aspartate transaminase (AST) > 120 U/L (OR = 25.853, p < 0.0001), triglycerides > 3 mmol/L (OR = 12.9833, p = 0.011)), ferritin > 1500 ng/mL (OR = 5.513, p = 0.050), as well as hemophagocytosis in bone puncture (OR = 18.132, p = 0.001) were highly associated with the occurrence of MAS. The mortality rate of total AOSD patients was 4.47%, MAS was the main cause of death in AOSD patients (OR = 11.705, 95%CI = 4.783-28.647, p < 0.0001). PLT <= 100 x 10(9)/L (p = 0.0001), fibrinogen < 1.5 g/L (p = 0.0286), splenomegaly (p = 0.0002), and liver dysfunction (p = 0.0008) highly suggested poor prognosis. Conclusion MAS occurrence is the major cause of death in AOSD patients. Notable liver dysfunction, as well as splenomegaly, low number of platelets or neutrophils, high levels of serum ferritin, and reduced level of fibrinogen are risk factors for poor outcome.
引用
收藏
页码:2379 / 2386
页数:8
相关论文
共 50 条
  • [1] Macrophage activation syndrome associated with adult-onset Still’s disease: a multicenter retrospective analysis
    Ran Wang
    Ting Li
    Shuang Ye
    Wenfeng Tan
    Cheng Zhao
    Yisha Li
    Chun de Bao
    Qiong Fu
    Clinical Rheumatology, 2020, 39 : 2379 - 2386
  • [2] Predictive factors and prognosis of macrophage activation syndrome associated with adult-onset Still's disease
    Yang, X. -P.
    Wang, M.
    Li, T. -F.
    Li, W.
    Zhang, L.
    Liu, S. -Y.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (06) : 83 - 88
  • [3] Clinical characteristics of macrophage activation syndrome in adult-onset Still's disease
    Gao, Q.
    Yuan, Y.
    Wang, Y.
    Jiang, J.
    Ye, Z.
    Liu, T.
    Jiang, Z.
    Zhao, L.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (05) : S59 - S66
  • [4] Macrophage activation syndrome with lung involvement complicating adult-onset Still's disease
    Wang, C. R.
    Tsai, Y. S.
    Mai, I. C.
    NETHERLANDS JOURNAL OF MEDICINE, 2018, 76 (10) : 442 - 449
  • [5] Adult-onset Still's disease with secondary macrophage activation syndrome: a case report
    Nicoletti, Giuseppe
    Bonelli, Antonio
    Clemente, Rocco
    Ciuffreda, Simona
    Dentamaro, Gaetano
    La Masa, Agata Tiziana
    Lascaro, Vito
    Santarcangelo, Pasquale
    ITALIAN JOURNAL OF MEDICINE, 2023, 17 (01)
  • [6] Macrophage activation syndrome complicating early course of adult-onset Still's disease
    Bozic, Ksenija
    Elez, Marija
    Glisic, Branislava
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2021, 149 (1-2) : 74 - 77
  • [7] Possible macrophage activation syndrome following initiation of adalimumab in a patient with adult-onset still's disease
    Souabni, Leila
    Dridi, Leila
    Ben Abdelghani, Kawther
    Kassab, Selma
    Chekili, Selma
    Laater, Ahmed
    Zakraoui, Leith
    PAN AFRICAN MEDICAL JOURNAL, 2014, 17
  • [8] Risk of macrophage activation syndrome in patients with adult-onset Still's disease with skin involvement: A retrospective cohort study
    Ding, Yuwei
    Tang, Shunli
    Li, Sheng
    Yang, Changyi
    Liu, Taoming
    Ying, Shuni
    Zhu, Dingxian
    Sun, Chuanyin
    Chen, Weiqian
    Shi, Yu
    Fang, Hong
    Qiao, Jianjun
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (06) : 1503 - 1509
  • [9] Ruxolitinib for Refractory Macrophage Activation Syndrome Complicating Adult-Onset Still's Disease
    Levy, Ofer
    Apel, Arie
    Alhdor, Hossam
    Mizrachi, Avraham
    Agmon-Levin, Nancy
    Koren-Michowitz, Maya
    Amit-Vazina, Mirit
    EUROPEAN JOURNAL OF RHEUMATOLOGY, 2022, 9 (04) : 217 - 220
  • [10] Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease
    Banse, Christopher
    Vittecoq, Olivier
    Benhamou, Ygal
    Gauthier-Prieur, Maud
    Lequerre, Thierry
    Levesque, Herve
    JOINT BONE SPINE, 2013, 80 (06) : 653 - 655